title: Oxymatrine improves TNBS-induced colitis in rats by inhibiting the expression of NF-kappaB p65.
abstract: Inflammatory bowel disease is thought to be regulated by the balance between Th1 and Th2 cytokines secreted by T cells, and NF-kappaB p65 also plays a predominant role in the intestinal inflammation. We evaluated the potency of oxymatrine, one of active components of Sophora Root, in inhibiting the immune responses and inflammation in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. The inflammation was markedly ameliorated in the oxymatrine-treated rats. The level of IL-2 was increased and that of IL-10 was decreased in colon tissue in the rat model, which was reversed by the treatment of oxymatrine. Moreover, the elevated expression of NF-kappaB p65 in colon tissue in the model was also improved by oxymatrine treatment. Our results suggest that oxymatrine might be beneficial for the abnormal immune responses and inflammation by regulating the unbalance of Th1 and Th2 cytokines secretion and inhibiting the expression of NF-kappaB p65 in colon tissue.
authors.affiliation: Department of Traditional Chinese Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. fanheng009@yahoo.com.cn
authors.forename: Heng
authors.initials: H
authors.lastname: Fan
authors.forename: Rui
authors.initials: R
authors.lastname: Chen
authors.forename: Lin
authors.initials: L
authors.lastname: Shen
authors.forename: Jianfang
authors.initials: J
authors.lastname: Lv
authors.forename: Pengcheng
authors.initials: P
authors.lastname: Xiong
authors.forename: Zhexing
authors.initials: Z
authors.lastname: Shou
authors.forename: Xiong
authors.initials: X
authors.lastname: Zhuang
mesh_terms: D000470:Alkaloids / Q000627:therapeutic use*; D000818:Animals; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy* / Q000201:enzymology; D003106:Colon / Q000378:metabolism; D015536:Down-Regulation / Q000187:drug effects; D016753:Interleukin-10 / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D008297:Male; D011807:Quinolizines / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D029909:Sophora / Q000737:chemistry; D051996:Transcription Factor RelA / Q000378:metabolism*; D014302:Trinitrobenzenesulfonic Acid; D000093842:Matrines
chemical_list: D000470:Alkaloids; D016753:Interleukin-10; D007376:Interleukin-2; D011807:Quinolizines; D051996:Transcription Factor RelA; D014302:Trinitrobenzenesulfonic Acid; C498145:Rela protein, rat; C037573:oxymatrine; D000093842:Matrines